FDA Removes Required REMS Program for Approval of Abecma and for Breyanzi
July 01, 2025
July 01, 2025
NORTH HOLLYWOOD, California, July 1 -- The International Myeloma Foundation issued the following news:
* * *
U.S. FDA Removes Required REMS Program for Approval of Abecma (ide-cel) and for Breyanzi (liso-cel)
According to a June 26th press release from Bristol Myers Squibb (BMS), "the U.S. Food and Drug Administration (FDA) has approved label updates for both of its CAR T cell therapies, Breyanzi(R) (lisocabtagene maraleucel; liso-cel) for the treatmen . . .
* * *
U.S. FDA Removes Required REMS Program for Approval of Abecma (ide-cel) and for Breyanzi (liso-cel)
According to a June 26th press release from Bristol Myers Squibb (BMS), "the U.S. Food and Drug Administration (FDA) has approved label updates for both of its CAR T cell therapies, Breyanzi(R) (lisocabtagene maraleucel; liso-cel) for the treatmen . . .